MIB-1 as a proliferative marker in transitional cell carcinoma of the bladder
Authors:
Abstract
BACKGROUND Staging and grading of transitional cell carcinoma of the bladder are generally viewed as indicators of prognosis and form the basis of therapy, but they do not predict outcome accurately. This study was designed to evaluate the value for predicting recurrence, progression, and survival of proliferation fraction in transitional cell carcinoma of the bladder determined by immunostaining of histopathologic specimens with the monoclonal antigen MIB‐1. METHODS In a prospectively followed group of 301 patients with transitional cell carcinoma of the bladder, formalin fixed tumor specimens were immunostained and the MIB‐1 labeling index was determined. Crude survival, progression free survival, and recurrence free survival (for patients with Ta and T1 tumors) were assessed in univariate and multivariate analysis according to stage, grade, mitotic index of the tumor, and patient age. The median value of continuous variables was used as a cutoff point in statistical analysis. RESULTS In univariate analysis there was a strong association between all included factors and crude survival, progression free survival, and recurrence free survival with a median follow‐up period of 60 months. In multivariate analysis, crude survival and progression free survival were determined by stage (P = 0.0001) and age (P = 0.0001). Recurrence free survival for patients with Ta and T1 tumors was determined by MIB‐1 labeling index (P = 0.0317), mitotic index (P = 0.0229), and age (P = 0.0001). CONCLUSIONS MIB‐1 immunostaining in transitional cell carcinoma of the bladder correlated well with grade, stage, and clinical outcome. In multivariate analysis, proliferation fraction had prognostic value in predicting recurrence free survival for patients with Ta and T1 tumors, whereas stage and age appeared to be predictors of progression free survival. Cancer 2000;88:2598–605. © 2000 American Cancer Society.Keywords
This publication has 19 references indexed in Scilit:
- Prognostic Value of Ki-67 for Recurrence and Progression of Superficial Bladder CancerJournal of Urology, 1997
- Correlation of morphometry, nucleolar organizer regions, proliferating cell nuclear antigen and Ki67 antigen expression with grading and staging in urinary bladder carcinomasBritish Journal of Urology, 1995
- Determination of cell proliferationMolecular Pathology, 1995
- A simplified grading method of transitional cell carcinoma of the urinary bladder: reproducibility, clinical significance and comparison with other prognostic parametersBritish Journal of Urology, 1994
- Growth Fractions in Bladder Cancer Defined by Ki67: Association with Cancer Grade, Category and Recurrence Rate of Superficial LesionsBritish Journal of Urology, 1993
- Proliferative activity of urothelial neoplasms: comparison of BrdU incorporation, Ki67 expression, and nucleolar organiser regions.Journal of Clinical Pathology, 1993
- Monoclonal antibodies against recombinant parts of the Ki‐67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave‐processed formalin‐fixed paraffin sectionsThe Journal of Pathology, 1992
- Grading in Superficial Bladder Cancer. (1) Morphological CriteriaBritish Journal of Urology, 1988
- Recurrence, Progression and Survival in Bladder CancerScandinavian Journal of Urology and Nephrology, 1987
- Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferationInternational Journal of Cancer, 1983